<!DOCTYPE html>
<html lang="en" dir="ltr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Duchenne Muscular Dystrophy Hub | CarePedia Information Center</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Rubik:wght@300;400;500;600;700;800;900&display=swap" rel="stylesheet">
<link rel="alternate" hreflang="he" href="https://carepedia.org/dmd" />
<link rel="alternate" hreflang="en" href="https://carepedia.org/en/dmd" />

<style>
* { margin: 0; padding: 0; box-sizing: border-box; }

:root {
  --primary: #0f4c75;
  --primary-light: #3282b8;
  --accent: #00b894;
  --accent-light: #55efc4;
  --warm: #fdcb6e;
  --warm-dark: #e17055;
  --bg: #f0f4f8;
  --card: #ffffff;
  --text: #2c3e50;
  --text-light: #5d6d7e;
  --shadow: 0 4px 20px rgba(0,0,0,0.08);
  --shadow-hover: 0 12px 40px rgba(0,0,0,0.18);
  --radius: 16px;
  --transition: all 0.3s cubic-bezier(.4,0,.2,1);
  /* Aliases for Iconify icons */
  --forest: #0f4c75;
  --forest-mid: #3282b8;
  --forest-light: rgba(50,130,184,0.12);
  --amber: #fdcb6e;
  --amber-light: rgba(253,203,110,0.12);
  --border: #dde4eb;
}

body {
  font-family: 'Rubik', 'Segoe UI', Tahoma, Arial, sans-serif;
  background: var(--bg);
  color: var(--text);
  line-height: 1.8;
  overflow-x: hidden;
  position: relative;
}

body::before {
  content: '';
  position: fixed;
  top: 0; left: 0; width: 100vw; height: 100vh;
  background:
    radial-gradient(ellipse at 10% 20%, rgba(15,76,117,0.07) 0%, transparent 50%),
    radial-gradient(ellipse at 90% 80%, rgba(0,184,148,0.07) 0%, transparent 50%),
    radial-gradient(ellipse at 50% 50%, rgba(253,203,110,0.05) 0%, transparent 60%);
  pointer-events: none;
  z-index: 0;
}

.scroll-progress {
  position: fixed;
  top: 0; right: 0;
  width: 100%; height: 4px;
  z-index: 2000;
  background: transparent;
}
.scroll-progress .bar {
  height: 100%; width: 0%;
  background: linear-gradient(90deg, var(--accent), var(--primary-light), var(--warm));
  border-radius: 0 0 0 4px;
  transition: width 0.1s linear;
}

.sidebar {
  position: fixed;
  top: 0; left: 0;
  width: 280px; height: 100vh;
  background: rgba(15,76,117,0.85);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border-right: 1px solid rgba(255,255,255,0.1);
  z-index: 1000;
  padding: 30px 20px;
  overflow-y: auto;
  transition: transform 0.4s cubic-bezier(.4,0,.2,1);
}
.sidebar .logo {
  text-align: center;
  margin-bottom: 30px;
  padding-bottom: 20px;
  border-bottom: 1px solid rgba(255,255,255,0.15);
}
.sidebar .logo .icon { font-size: 48px; }
.sidebar .logo h2 { color: #fff; font-size: 18px; margin-top: 8px; font-weight: 600; }
.sidebar nav a {
  display: flex; align-items: center; gap: 12px;
  padding: 14px 18px; color: rgba(255,255,255,0.8);
  text-decoration: none; border-radius: 12px;
  margin-bottom: 4px; font-size: 15px; transition: var(--transition);
}
.sidebar nav a:hover, .sidebar nav a.active {
  background: rgba(255,255,255,0.15); color: #fff; transform: translateX(4px);
}
.sidebar nav a .nav-icon { font-size: 22px; min-width: 30px; text-align: center; }

.menu-toggle {
  display: none;
  position: fixed;
  top: 20px; left: 20px;
  z-index: 1100;
  background: var(--primary); color: #fff;
  border: none; border-radius: 12px;
  width: 50px; height: 50px; font-size: 24px;
  cursor: pointer; box-shadow: var(--shadow); transition: var(--transition);
}
.menu-toggle:hover { transform: scale(1.05); }
.menu-toggle.open { border-radius: 50%; background: var(--warm-dark); }

.main {
  margin-left: 280px;
  min-height: 100vh;
  position: relative;
  z-index: 1;
}

.hero {
  background: linear-gradient(135deg, var(--primary) 0%, #3282b8 40%, var(--accent) 100%);
  padding: 80px 60px;
  color: #fff;
  position: relative;
  overflow: hidden;
}
.hero::before {
  content: '';
  position: absolute;
  top: -50%; left: -50%;
  width: 200%; height: 200%;
  background: radial-gradient(circle, rgba(255,255,255,0.05) 0%, transparent 60%);
  animation: float 20s linear infinite;
}
@keyframes float { 0% { transform: rotate(0deg); } 100% { transform: rotate(360deg); } }
.hero-content { position: relative; z-index: 1; max-width: 900px; }
.hero h1 { font-size: 52px; font-weight: 800; margin-bottom: 10px; line-height: 1.3; }
.hero .greeting { font-size: 22px; opacity: 0.95; margin-bottom: 30px; line-height: 1.7; }
.hero .subtitle { font-size: 18px; opacity: 0.8; max-width: 700px; }

.fade-in { opacity: 0; transform: translateY(30px); transition: opacity 0.7s ease, transform 0.7s ease; }
.fade-in.visible { opacity: 1; transform: translateY(0); }

.section { padding: 60px; max-width: 1100px; margin: 0 auto; }
.section-header {
  display: flex; align-items: center; gap: 16px;
  margin-bottom: 40px; padding-bottom: 20px;
  border-bottom: 3px solid var(--primary-light);
}
.section-header .sec-icon { font-size: 42px; }
.section-header h2 { font-size: 36px; color: var(--primary); }
.section-header p { color: var(--text-light); font-size: 16px; margin-top: 4px; }

.cards-grid {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
  gap: 24px; margin-bottom: 40px;
}
.card {
  background: var(--card); border-radius: var(--radius); padding: 30px;
  box-shadow: var(--shadow); transition: var(--transition);
  border-top: 4px solid var(--primary-light);
  position: relative; overflow: hidden;
}
.card:hover { transform: translateY(-6px) scale(1.01); box-shadow: var(--shadow-hover); }
.card .card-icon { font-size: 40px; margin-bottom: 16px; }
.card h3 { font-size: 20px; color: var(--primary); margin-bottom: 12px; }
.card p { color: var(--text-light); font-size: 15px; line-height: 1.8; }
.card.green { border-top-color: var(--accent); }
.card.orange { border-top-color: var(--warm); }
.card.blue { border-top-color: var(--primary-light); }

.cat-grid {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(240px, 1fr));
  gap: 20px; margin-top: 40px;
}
.cat-card {
  background: var(--card); border-radius: var(--radius); padding: 30px 24px;
  text-align: center; cursor: pointer; transition: var(--transition);
  box-shadow: var(--shadow); text-decoration: none; color: var(--text);
}
.cat-card:hover { transform: translateY(-6px) scale(1.02); box-shadow: var(--shadow-hover); }
.cat-card .cat-icon { font-size: 48px; margin-bottom: 14px; }
.cat-card h3 { font-size: 18px; color: var(--primary); margin-bottom: 8px; }
.cat-card p { font-size: 13px; color: var(--text-light); }

.accordion { margin-bottom: 16px; }
.accordion-header {
  background: var(--card); padding: 20px 24px; border-radius: var(--radius);
  cursor: pointer; display: flex; justify-content: space-between; align-items: center;
  box-shadow: var(--shadow); transition: var(--transition);
  font-size: 17px; font-weight: 600; color: var(--primary);
}
.accordion-header:hover { background: #eef4fb; }
.accordion-header .arrow { transition: transform 0.3s ease; font-size: 20px; }
.accordion-header.open .arrow { transform: rotate(180deg); }
.accordion-body {
  max-height: 0; overflow: clip; transition: max-height 0.4s ease;
  background: var(--card); border-radius: 0 0 var(--radius) var(--radius); margin-top: -8px;
}
.accordion-body .inner { padding: 20px 24px 24px; color: var(--text-light); line-height: 2; }

.tabs { display: flex; gap: 8px; margin-bottom: 24px; flex-wrap: wrap; }
.tab-btn {
  padding: 12px 24px; background: var(--card);
  border: 2px solid #dde4eb; border-radius: 30px;
  cursor: pointer; font-size: 15px; font-family: inherit;
  color: var(--text-light); transition: var(--transition);
}
.tab-btn:hover { border-color: var(--primary-light); color: var(--primary); }
.tab-btn.active { background: var(--primary); color: #fff; border-color: var(--primary); }
.tab-content { display: none; animation: fadeIn 0.4s ease; }
.tab-content.active { display: block; }
@keyframes fadeIn { from { opacity: 0; transform: translateY(10px); } to { opacity: 1; transform: translateY(0); } }

.info-box {
  background: linear-gradient(135deg, #eaf4fb 0%, #e8f8f0 100%);
  border-radius: var(--radius); padding: 24px 28px; margin: 24px 0;
  border-left: 5px solid var(--primary-light);
}
.info-box.warning { background: linear-gradient(135deg, #fef9e7 0%, #fdebd0 100%); border-left-color: var(--warm); }
.info-box.success { background: linear-gradient(135deg, #e8f8f0 0%, #d5f5e3 100%); border-left-color: var(--accent); }
.info-box h4 { color: var(--primary); margin-bottom: 8px; font-size: 17px; }
.info-box p { color: var(--text-light); font-size: 15px; }

.link-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 12px 24px; background: var(--primary);
  color: #fff; text-decoration: none; border-radius: 30px;
  font-size: 15px; transition: var(--transition); margin: 6px;
}
.link-btn:hover { background: var(--primary-light); transform: translateY(-2px); }
.link-btn.green { background: var(--accent); }
.link-btn.green:hover { background: var(--accent-light); color: var(--text); }
.link-btn.orange { background: var(--warm-dark); }
.link-btn.orange:hover { background: var(--warm); color: var(--text); }

.styled-table {
  width: 100%; border-collapse: collapse; margin: 20px 0;
  background: var(--card); border-radius: var(--radius);
  overflow: hidden; box-shadow: var(--shadow);
}
.styled-table thead { background: var(--primary); color: #fff; }
.styled-table th { padding: 16px 20px; text-align: left; font-weight: 600; }
.styled-table td { padding: 14px 20px; border-bottom: 1px solid #eee; }
.styled-table tbody tr:hover { background: #f7fafc; }

.timeline { position: relative; padding-left: 40px; margin: 30px 0; }
.timeline::before {
  content: '';
  position: absolute; left: 12px; top: 0; bottom: 0;
  width: 3px;
  background: linear-gradient(to bottom, var(--primary-light), var(--accent));
  border-radius: 3px;
}
.timeline-item {
  position: relative; margin-bottom: 30px; padding: 24px;
  background: var(--card); border-radius: var(--radius); box-shadow: var(--shadow);
}
.timeline-item::before {
  content: ''; position: absolute;
  left: -34px; top: 30px;
  width: 16px; height: 16px;
  background: var(--accent); border-radius: 50%; border: 3px solid var(--bg);
}
.timeline-item h4 { color: var(--primary); font-size: 18px; margin-bottom: 8px; }
.timeline-item p { color: var(--text-light); }
.timeline-item .time-label {
  display: inline-block; background: var(--primary); color: #fff;
  padding: 4px 14px; border-radius: 20px; font-size: 13px; margin-bottom: 10px;
}

.stats-row {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(200px, 1fr));
  gap: 20px; margin: 30px 0;
}
.stat-box {
  background: linear-gradient(135deg, var(--card) 0%, #f7fafc 100%);
  border-radius: var(--radius); padding: 24px; text-align: center;
  box-shadow: var(--shadow); border-bottom: 3px solid var(--primary-light);
  transition: var(--transition);
}
.stat-box:nth-child(2) { border-bottom-color: var(--accent); }
.stat-box:nth-child(3) { border-bottom-color: var(--warm); }
.stat-box:nth-child(4) { border-bottom-color: var(--warm-dark); }
.stat-box:hover { transform: translateY(-4px); box-shadow: var(--shadow-hover); }
.stat-box .stat-num {
  font-size: 36px; font-weight: 800;
  background: linear-gradient(135deg, var(--primary), var(--accent));
  -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text;
}
.stat-box .stat-label { color: var(--text-light); font-size: 14px; margin-top: 6px; }

.carepedia-cta {
  background: linear-gradient(135deg, #1A73E8, #00C9A7);
  padding: 48px 24px; text-align: center; color: #fff;
}
.carepedia-cta h3 { font-size: 24px; font-weight: 700; margin-bottom: 12px; }
.carepedia-cta p { font-size: 16px; opacity: 0.9; margin-bottom: 24px; max-width: 500px; margin-left: auto; margin-right: auto; }
.carepedia-cta .cta-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 14px 32px; background: #fff; color: #1A73E8;
  text-decoration: none; border-radius: 30px; font-size: 16px; font-weight: 700;
  font-family: inherit; transition: all 0.3s ease; box-shadow: 0 4px 16px rgba(0,0,0,0.15);
}
.carepedia-cta .cta-btn:hover { transform: translateY(-2px); box-shadow: 0 8px 24px rgba(0,0,0,0.2); }

.credit-bar {
  display: flex; align-items: center; justify-content: center; gap: 16px; flex-wrap: wrap;
  padding: 14px 20px; font-size: 14px; color: rgba(255,255,255,0.85); position: relative; z-index: 1;
}
.credit-bar span { opacity: 0.9; }
.portal-request-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 10px 22px; background: var(--primary-light); color: #fff;
  text-decoration: none; border-radius: 30px; font-size: 14px;
  font-family: inherit; font-weight: 600; transition: var(--transition);
  box-shadow: 0 2px 12px rgba(0,0,0,0.15);
}
.portal-request-btn:hover { background: var(--primary); transform: translateY(-2px); box-shadow: 0 4px 20px rgba(0,0,0,0.2); }

.footer {
  background: var(--primary); color: rgba(255,255,255,0.8);
  text-align: center; padding: 40px; font-size: 14px;
}

.scroll-top {
  position: fixed; bottom: 30px; left: 30px;
  width: 50px; height: 50px; background: var(--primary);
  color: #fff; border: none; border-radius: 50%;
  font-size: 22px; cursor: pointer; box-shadow: var(--shadow);
  transition: var(--transition); opacity: 0; pointer-events: none; z-index: 999;
}
.scroll-top.visible { opacity: 1; pointer-events: auto; }
.scroll-top:hover { background: var(--primary-light); transform: translateY(-3px); }

.search-box { position: relative; margin: 0 auto; }
.search-box input {
  width: 100%; padding: 14px 20px 14px 50px;
  border: 2px solid rgba(15,76,117,0.15); border-radius: 30px;
  font-size: 16px; font-family: 'Rubik', sans-serif;
  background: var(--card); color: var(--text); transition: var(--transition);
  box-sizing: border-box;
}
.search-box input:focus { outline: none; border-color: var(--primary-light); box-shadow: 0 0 0 4px rgba(50,130,184,0.1); }
.search-box .search-icon {
  position: absolute; left: 18px; top: 50%;
  transform: translateY(-50%); font-size: 20px; pointer-events: none;
}

.sidebar-overlay {
  display: none; position: fixed; top: 0; left: 0; right: 0; bottom: 0;
  background: rgba(0,0,0,0.5); z-index: 999; opacity: 0; transition: opacity 0.3s ease;
}
.sidebar-overlay.active { display: block; opacity: 1; }

@media (max-width: 900px) {
  .sidebar { transform: translateX(-100%); width: 270px; }
  .sidebar.open { transform: translateX(0); }
  .menu-toggle { display: block; }
  .main { margin-left: 0; }
  .hero { padding: 60px 30px; }
  .section { padding: 40px 24px; }
}

@media (max-width: 768px) {
  .sidebar { transform: translateX(-100%); width: 260px; }
  .sidebar.open { transform: translateX(0); }
  .menu-toggle { display: block; }
  .main { margin-left: 0; }
  .hero { padding: 40px 20px 36px; }
  .hero h1 { font-size: 28px; line-height: 1.3; }
  .hero .greeting { font-size: 16px; line-height: 1.7; }
  .hero .subtitle { font-size: 14px; }
  .section { padding: 28px 16px; }
  .section-header { flex-direction: column; align-items: flex-start; gap: 8px; margin-bottom: 24px; padding-bottom: 14px; }
  .section-header .sec-icon { font-size: 32px; }
  .section-header h2 { font-size: 24px; }
  .section-header p { font-size: 14px; }
  .cards-grid { grid-template-columns: 1fr; gap: 16px; margin-bottom: 24px; }
  .card { padding: 20px; }
  .card:hover { transform: none; }
  .cat-card:hover { transform: none; }
  .stat-box:hover { transform: none; }
  .link-btn:hover { transform: none; }
  .portal-request-btn:hover { transform: none; }
  .scroll-top:hover { transform: none; }
  .sidebar nav a:hover { transform: none; }
  .card .card-icon { font-size: 32px; margin-bottom: 10px; }
  .card h3 { font-size: 17px; }
  .card p { font-size: 14px; }
  .cat-grid { grid-template-columns: repeat(2, 1fr); gap: 12px; margin-top: 24px; }
  .cat-card { padding: 18px 12px; }
  .cat-card .cat-icon { font-size: 32px; margin-bottom: 8px; }
  .cat-card h3 { font-size: 14px; }
  .cat-card p { font-size: 11px; }
  .stats-row { grid-template-columns: repeat(2, 1fr); gap: 12px; margin: 20px 0; }
  .stat-box { padding: 16px 10px; }
  .stat-box .stat-num { font-size: 26px; }
  .stat-box .stat-label { font-size: 12px; }
  .tabs { gap: 6px; margin-bottom: 16px; }
  .tab-btn { padding: 8px 14px; font-size: 13px; border-radius: 20px; }
  .styled-table { display: block; overflow-x: auto; -webkit-overflow-scrolling: touch; font-size: 13px; }
  .styled-table th { padding: 10px 12px; font-size: 13px; white-space: nowrap; }
  .styled-table td { padding: 10px 12px; font-size: 13px; min-width: 100px; }
  .info-box { padding: 16px 18px; margin: 16px 0; }
  .info-box h4 { font-size: 15px; }
  .info-box p { font-size: 13px; }
  .accordion-header { padding: 14px 16px; font-size: 15px; }
  .accordion-body .inner { padding: 14px 16px 18px; font-size: 14px; line-height: 1.9; }
  .timeline { padding-left: 30px; margin: 20px 0; }
  .timeline-item { padding: 16px; margin-bottom: 20px; }
  .timeline-item::before { left: -24px; width: 12px; height: 12px; top: 22px; }
  .timeline-item h4 { font-size: 16px; }
  .timeline-item p { font-size: 13px; }
  .link-btn { padding: 10px 16px; font-size: 13px; margin: 4px 2px; }
  .search-box input { padding: 12px 18px 12px 40px; font-size: 14px; }
  .footer { padding: 28px 16px; font-size: 13px; }
  .scroll-top { width: 42px; height: 42px; font-size: 18px; bottom: 20px; left: 16px; }
}

@media (max-width: 380px) {
  .hero h1 { font-size: 24px; }
  .hero .greeting { font-size: 15px; }
  .cat-grid { grid-template-columns: 1fr 1fr; gap: 8px; }
  .cat-card { padding: 14px 8px; }
  .cat-card .cat-icon { font-size: 26px; }
  .cat-card h3 { font-size: 13px; }
  .cat-card p { display: none; }
  .stats-row { grid-template-columns: 1fr 1fr; gap: 8px; }
  .stat-box .stat-num { font-size: 22px; }
  .section { padding: 20px 12px; }
  .tab-btn { padding: 7px 10px; font-size: 12px; }
}

.disclaimer-banner {
  background: linear-gradient(135deg, #FFF3E0, #FFF8E1);
  border-bottom: 2px solid #FFB74D;
  padding: 10px 20px; text-align: center; font-size: 13px; color: #5D4037;
  position: relative; z-index: 1500;
  display: flex; align-items: center; justify-content: center; gap: 8px; flex-wrap: wrap;
}
.disclaimer-banner strong { color: #E65100; }
.disclaimer-banner a { color: #1A73E8; text-decoration: underline; font-weight: 600; }
.disclaimer-banner a:hover { color: #0D47A1; }
@media (max-width: 768px) { .disclaimer-banner { font-size: 12px; padding: 8px 12px; } }
</style>
<script src="https://code.iconify.design/iconify-icon/2.1.0/iconify-icon.min.js" defer></script>
</head>
<body>

<div class="scroll-progress"><div class="bar" id="scrollBar"></div></div>
<div class="sidebar-overlay" id="overlay" onclick="closeMenu()"></div>

<button class="menu-toggle" id="menuToggle" onclick="toggleMenu()">
  <iconify-icon icon="mdi:menu"></iconify-icon>
</button>

<aside class="sidebar" id="sidebar">
  <div class="logo">
    <div class="icon"><iconify-icon icon="mdi:dna" style="color:#fff;font-size:48px;"></iconify-icon></div>
    <h2>DMD Hub<br><span style="font-size:13px;opacity:0.8;">Duchenne Muscular Dystrophy</span></h2>
  </div>
  <nav>
    <a href="#home" class="active" onclick="navigateTo('home')"><span class="nav-icon"><iconify-icon icon="mdi:home"></iconify-icon></span> Home</a>
    <a href="#about" onclick="navigateTo('about')"><span class="nav-icon"><iconify-icon icon="mdi:information"></iconify-icon></span> About DMD</a>
    <a href="#treatments" onclick="navigateTo('treatments')"><span class="nav-icon"><iconify-icon icon="mdi:pill"></iconify-icon></span> Treatments</a>
    <a href="#trials" onclick="navigateTo('trials')"><span class="nav-icon"><iconify-icon icon="mdi:flask"></iconify-icon></span> Clinical Trials</a>
    <a href="#research" onclick="navigateTo('research')"><span class="nav-icon"><iconify-icon icon="mdi:microscope"></iconify-icon></span> Research</a>
    <a href="#physio" onclick="navigateTo('physio')"><span class="nav-icon"><iconify-icon icon="mdi:run"></iconify-icon></span> Physiotherapy</a>
    <a href="#lifestyle" onclick="navigateTo('lifestyle')"><span class="nav-icon"><iconify-icon icon="mdi:heart"></iconify-icon></span> Lifestyle</a>
    <a href="#psychological-approach" onclick="navigateTo('psychological-approach')"><span class="nav-icon"><iconify-icon icon="mdi:brain"></iconify-icon></span> Psychological Support</a>
    <a href="#stories" onclick="navigateTo('stories')"><span class="nav-icon"><iconify-icon icon="mdi:account-voice"></iconify-icon></span> Stories</a>
    <a href="#books" onclick="navigateTo('books')"><span class="nav-icon"><iconify-icon icon="mdi:book-open"></iconify-icon></span> Books &amp; Media</a>
    <a href="#action" onclick="navigateTo('action')"><span class="nav-icon"><iconify-icon icon="mdi:clipboard-check"></iconify-icon></span> Action Plan</a>
    <a href="#resources" onclick="navigateTo('resources')"><span class="nav-icon"><iconify-icon icon="mdi:link"></iconify-icon></span> Resources</a>
  </nav>
</aside>

<main class="main">

  <div class="disclaimer-banner">
    <iconify-icon icon="mdi:alert-circle-outline" style="font-size:18px;color:#E65100;"></iconify-icon>
    <strong>Medical Disclaimer:</strong> This portal is for informational purposes only and does not replace professional medical advice.
    Always consult a qualified physician before making any medical decision.
  </div>

  <!-- HOME -->
  <section id="home" class="hero">
    <div class="hero-content">
      <h1><iconify-icon icon="mdi:dna" style="vertical-align:middle;margin-right:12px;"></iconify-icon>Duchenne Muscular Dystrophy</h1>
      <p class="greeting">A comprehensive, evidence-based information hub for patients, families and caregivers — treatments, clinical trials, research, and community resources.</p>
      <p class="subtitle">DMD is the most common severe muscular dystrophy, affecting approximately 1 in 3,500 males worldwide. This portal is updated regularly with the latest approved therapies and research developments.</p>
    </div>
  </section>

  <div class="section fade-in">
    <div class="stats-row">
      <div class="stat-box"><div class="stat-num">1:3,500</div><div class="stat-label">Prevalence in males</div></div>
      <div class="stat-box"><div class="stat-num">300K+</div><div class="stat-label">People affected worldwide</div></div>
      <div class="stat-box"><div class="stat-num">2–5</div><div class="stat-label">Age of first symptoms (years)</div></div>
      <div class="stat-box"><div class="stat-num">79</div><div class="stat-label">Exons in the dystrophin gene</div></div>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="mdi:dna"></iconify-icon></div>
        <h3>What is DMD?</h3>
        <p>Duchenne Muscular Dystrophy is caused by mutations in the DMD gene (Xp21) that prevent production of functional dystrophin — a protein critical for muscle cell integrity. Muscles progressively weaken over time.</p>
      </div>
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="mdi:pill"></iconify-icon></div>
        <h3>Available Treatments</h3>
        <p>Steroids (prednisone, deflazacort, vamorolone), exon-skipping therapies (eteplirsen, golodirsen, viltolarsen, casimersen), gene therapy (Elevidys), and givinostat — approved in 2024.</p>
      </div>
      <div class="card orange">
        <div class="card-icon"><iconify-icon icon="mdi:flask"></iconify-icon></div>
        <h3>Clinical Trials</h3>
        <p>Dozens of active trials worldwide — CRISPR editing, next-generation gene therapy, novel exon skipping. Several trials with patient registries open globally.</p>
      </div>
    </div>

    <div class="cat-grid">
      <a class="cat-card" onclick="navigateTo('about')"><div class="cat-icon"><iconify-icon icon="mdi:information-outline"></iconify-icon></div><h3>About DMD</h3><p>Causes, genetics &amp; diagnosis</p></a>
      <a class="cat-card" onclick="navigateTo('treatments')"><div class="cat-icon"><iconify-icon icon="mdi:pill"></iconify-icon></div><h3>Treatments</h3><p>Approved therapies</p></a>
      <a class="cat-card" onclick="navigateTo('trials')"><div class="cat-icon"><iconify-icon icon="mdi:flask"></iconify-icon></div><h3>Clinical Trials</h3><p>Active research studies</p></a>
      <a class="cat-card" onclick="navigateTo('research')"><div class="cat-icon"><iconify-icon icon="mdi:microscope"></iconify-icon></div><h3>Research</h3><p>Latest discoveries</p></a>
      <a class="cat-card" onclick="navigateTo('physio')"><div class="cat-icon"><iconify-icon icon="mdi:run"></iconify-icon></div><h3>Physiotherapy</h3><p>Movement &amp; function</p></a>
      <a class="cat-card" onclick="navigateTo('lifestyle')"><div class="cat-icon"><iconify-icon icon="mdi:heart"></iconify-icon></div><h3>Lifestyle</h3><p>Nutrition, education &amp; tech</p></a>
      <a class="cat-card" onclick="navigateTo('stories')"><div class="cat-icon"><iconify-icon icon="mdi:account-voice"></iconify-icon></div><h3>Stories</h3><p>Personal experiences</p></a>
      <a class="cat-card" onclick="navigateTo('resources')"><div class="cat-icon"><iconify-icon icon="mdi:link"></iconify-icon></div><h3>Resources</h3><p>Organizations &amp; links</p></a>
    </div>
  </div>

  <!-- ABOUT -->
  <section id="about" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:information"></iconify-icon></div>
      <div><h2>About Duchenne Muscular Dystrophy</h2><p>Genetics, mechanism, and diagnosis</p></div>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="mdi:dna"></iconify-icon></div>
        <h3>The Dystrophin Gene</h3>
        <p>DMD is caused by mutations in the DMD gene on the X chromosome (Xp21) — the largest gene in the human genome with 79 exons. Mutations (deletions, duplications, point mutations) disrupt the reading frame, preventing production of functional dystrophin protein.</p>
      </div>
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="mdi:human-male"></iconify-icon></div>
        <h3>Who Is Affected</h3>
        <p>DMD is X-linked recessive. It primarily affects males (1 in 3,500), while females are usually carriers. Rarely, females with Turner syndrome (45,X) or unfavorable X-inactivation may also be symptomatic.</p>
      </div>
      <div class="card orange">
        <div class="card-icon"><iconify-icon icon="mdi:alert"></iconify-icon></div>
        <h3>First Symptoms</h3>
        <p>Symptoms typically appear between ages 2–5: delays in walking, frequent falls, difficulty climbing stairs or rising from the floor (Gowers' sign), calf enlargement (pseudohypertrophy), and elevated creatine kinase levels.</p>
      </div>
    </div>

    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">How is DMD diagnosed? <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>Diagnosis typically begins with a blood test showing markedly elevated creatine kinase (CK) levels — often 10–100 times normal. This is followed by genetic testing (NGS or MLPA) to identify the specific mutation. In some cases, muscle biopsy (showing absent dystrophin on immunostaining) is used for confirmation. Newborn screening for DMD has been introduced in some US states and is expanding globally.</p>
      </div></div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Disease progression <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>DMD progresses in stages: early ambulatory (ages 2–7), late ambulatory (ages 7–12), early non-ambulatory (teens), and late non-ambulatory (adulthood). Most boys lose independent walking by age 10–12. As the disease progresses, respiratory muscles and cardiac muscle become involved. With modern care, many patients now survive into their 30s and beyond.</p>
      </div></div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Becker Muscular Dystrophy (BMD) <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>BMD is caused by in-frame DMD mutations that allow production of a shorter but partially functional dystrophin. BMD is milder than DMD — some patients walk into adulthood. The exon-skipping concept is based on converting DMD-type mutations into BMD-like mutations by skipping specific exons to restore the reading frame.</p>
      </div></div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Cardiac and respiratory involvement <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>The heart muscle is also dystrophin-dependent. Most DMD patients develop dilated cardiomyopathy by adolescence. Cardiac monitoring (echocardiogram, MRI) and prophylactic cardiac medications (ACE inhibitors, beta-blockers) are standard of care. Respiratory monitoring and timely initiation of non-invasive ventilation (BiPAP/ventilator) are critical for survival.</p>
      </div></div>
    </div>
  </section>

  <!-- TREATMENTS -->
  <section id="treatments" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:pill"></iconify-icon></div>
      <div><h2>Treatments</h2><p>Approved therapies and medications</p></div>
    </div>

    <div class="tabs">
      <button class="tab-btn active" onclick="switchTab(this,'steroids')">Corticosteroids</button>
      <button class="tab-btn" onclick="switchTab(this,'exon-skipping')">Exon Skipping</button>
      <button class="tab-btn" onclick="switchTab(this,'gene-therapy')">Gene Therapy</button>
      <button class="tab-btn" onclick="switchTab(this,'other-meds')">Other Medications</button>
    </div>

    <div id="steroids" class="tab-content active">
      <div class="info-box success">
        <h4>Corticosteroids — Standard of Care</h4>
        <p>Corticosteroids are the backbone of DMD treatment. They slow disease progression by reducing inflammation and preserving muscle function. Treatment typically begins at ages 4–5, when motor function peaks.</p>
      </div>
      <table class="styled-table">
        <thead><tr><th>Medication</th><th>Dosing</th><th>Key Notes</th></tr></thead>
        <tbody>
          <tr><td><strong>Prednisone</strong></td><td>0.75 mg/kg/day daily</td><td>Most widely used globally; long safety record</td></tr>
          <tr><td><strong>Deflazacort (Emflaza)</strong></td><td>0.9 mg/kg/day daily</td><td>FDA-approved 2017; less weight gain than prednisone; available in US and select countries</td></tr>
          <tr><td><strong>Vamorolone (Agamree)</strong></td><td>6 mg/kg/day daily</td><td>FDA-approved October 2023; dissociative steroid with fewer side effects; improved bone safety profile</td></tr>
        </tbody>
      </table>
      <div class="info-box warning">
        <h4>Important: Side Effect Monitoring</h4>
        <p>All corticosteroids carry risks: weight gain, behavioral changes, bone density loss, cataracts, and growth effects. Regular monitoring by a multidisciplinary team is essential. Never stop steroids abruptly — taper under physician supervision.</p>
      </div>
    </div>

    <div id="exon-skipping" class="tab-content">
      <div class="info-box">
        <h4>Exon Skipping — Mutation-Specific Therapy</h4>
        <p>Exon skipping uses antisense oligonucleotides (ASOs) to "skip" specific exons during pre-mRNA splicing, restoring the reading frame and enabling production of a shorter but partially functional dystrophin — similar to the milder BMD protein. Each therapy targets specific exon mutations and is only effective for patients with those mutations.</p>
      </div>
      <table class="styled-table">
        <thead><tr><th>Drug</th><th>Target Exon</th><th>Brand</th><th>FDA Approval</th></tr></thead>
        <tbody>
          <tr><td><strong>Eteplirsen</strong></td><td>Exon 51</td><td>Exondys 51</td><td>2016 (accelerated)</td></tr>
          <tr><td><strong>Golodirsen</strong></td><td>Exon 53</td><td>Vyondys 53</td><td>2019 (accelerated)</td></tr>
          <tr><td><strong>Viltolarsen</strong></td><td>Exon 53</td><td>Viltepso</td><td>2020 (accelerated)</td></tr>
          <tr><td><strong>Casimersen</strong></td><td>Exon 45</td><td>Amondys 45</td><td>2021 (accelerated)</td></tr>
        </tbody>
      </table>
      <div class="info-box warning">
        <h4>Eligibility Check</h4>
        <p>Only ~13% of DMD patients are eligible for exon 51 skipping, ~8% for exon 53, ~9% for exon 45. Genetic testing must confirm the specific exon deletion before considering these therapies. Contact PPMD's newborn screening and genetic counseling programs for eligibility assessment.</p>
      </div>
    </div>

    <div id="gene-therapy" class="tab-content">
      <div class="info-box">
        <h4>Elevidys (Delandistrogene Moxeparvovec) — First Gene Therapy for DMD</h4>
        <p>Elevidys delivers a shortened version of the dystrophin gene (micro-dystrophin) via an AAV rh74 vector. FDA-approved in June 2023 (accelerated) and expanded in June 2024 for patients ages 4 and older who are ambulatory. Price: approximately $3.2 million per treatment.</p>
      </div>
      <div class="info-box warning">
        <h4>Black Box Warning — 2025 Update</h4>
        <p>In 2025, the FDA added a black box warning to Elevidys regarding serious immune-mediated myositis reactions following treatment. Patients must be monitored closely in the weeks following infusion. The FDA also required additional confirmatory trial data from Sarepta Therapeutics.</p>
      </div>
      <div class="accordion">
        <div class="accordion-header" onclick="toggleAccordion(this)">Who is eligible for Elevidys? <span class="arrow">&#9660;</span></div>
        <div class="accordion-body"><div class="inner">
          <p>Patients must be 4 years of age or older, ambulatory (able to walk), and must not have pre-existing antibodies to the AAVrh74 vector. Patients with certain immune conditions or prior gene therapy are excluded. A comprehensive pre-treatment screening is required at a specialized DMD center.</p>
        </div></div>
      </div>
      <div class="accordion">
        <div class="accordion-header" onclick="toggleAccordion(this)">What does micro-dystrophin do? <span class="arrow">&#9660;</span></div>
        <div class="accordion-body"><div class="inner">
          <p>The full-length dystrophin gene (2.4 million base pairs) is too large for AAV delivery. Elevidys uses a shortened construct (micro-dystrophin) that retains key functional domains of the protein. While not identical to full-length dystrophin, micro-dystrophin can partially stabilize the muscle membrane and reduce damage during contraction.</p>
        </div></div>
      </div>
    </div>

    <div id="other-meds" class="tab-content">
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon"><iconify-icon icon="mdi:pill"></iconify-icon></div>
          <h3>Givinostat (Duvyzat)</h3>
          <p>FDA-approved March 2024 for patients 6 and older. A histone deacetylase (HDAC) inhibitor that reduces fibrosis and inflammation in muscle tissue. Taken orally, twice daily with food. Effective regardless of specific mutation type.</p>
        </div>
        <div class="card green">
          <div class="card-icon"><iconify-icon icon="mdi:heart-pulse"></iconify-icon></div>
          <h3>Cardiac Medications</h3>
          <p>ACE inhibitors (enalapril, lisinopril) and beta-blockers (carvedilol, metoprolol) are recommended to protect the heart, often started prophylactically at ages 10–12 even before cardiac symptoms appear. Eplerenone may be added as cardiomyopathy progresses.</p>
        </div>
        <div class="card orange">
          <div class="card-icon"><iconify-icon icon="mdi:bone"></iconify-icon></div>
          <h3>Bone Health</h3>
          <p>Long-term steroid use reduces bone density. Calcium and vitamin D supplementation are standard. Bisphosphonates (zoledronic acid) may be prescribed if vertebral fractures occur. Regular DXA scans to monitor bone density are recommended.</p>
        </div>
      </div>
      <div class="info-box">
        <h4>Questions to Ask Your DMD Specialist</h4>
        <p>Which treatments am I genetically eligible for? When should we start steroids, and which type? Should we begin cardiac medications prophylactically? Is there an active clinical trial I qualify for? What is the cardiac and respiratory monitoring schedule?</p>
      </div>
    </div>
  </section>

  <!-- CLINICAL TRIALS -->
  <section id="trials" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:flask"></iconify-icon></div>
      <div><h2>Clinical Trials</h2><p>Active research studies and how to participate</p></div>
    </div>

    <div class="tabs">
      <button class="tab-btn active" onclick="switchTab(this,'gene-trials')">Gene Therapy Trials</button>
      <button class="tab-btn" onclick="switchTab(this,'crispr-trials')">CRISPR &amp; Genome Editing</button>
      <button class="tab-btn" onclick="switchTab(this,'intl-access')">Global Access</button>
      <button class="tab-btn" onclick="switchTab(this,'novel-trials')">Novel Approaches</button>
    </div>

    <div id="gene-trials" class="tab-content active">
      <div class="timeline">
        <div class="timeline-item">
          <div class="time-label">Solid Biosciences</div>
          <h4>SGT-003 — Next-Generation Gene Therapy</h4>
          <p>Phase 1/2 trial (INSPIRE DUCHENNE). SGT-003 uses a novel AAVhSC17 vector with a new micro-dystrophin construct. Early results (2024) show robust expression. Enrollment open at major US and EU sites.</p>
        </div>
        <div class="timeline-item">
          <div class="time-label">Genethon</div>
          <h4>GNT-0004</h4>
          <p>European gene therapy program using an AAV9 vector delivering a shortened dystrophin construct. Phase 1/2 studies in France and EU sites. Funded in part by the French Muscular Dystrophy Association (AFM-Téléthon).</p>
        </div>
        <div class="timeline-item">
          <div class="time-label">REGENXBIO</div>
          <h4>RGX-202</h4>
          <p>Phase 1/2 AFFINITY DUCHENNE trial. RGX-202 delivers a microdystrophin construct via AAVrh74 vector. Sites across the US and EU. Enrollment for ambulatory boys ages 4 and older.</p>
        </div>
        <div class="timeline-item">
          <div class="time-label">Pfizer</div>
          <h4>Program Halted (2023)</h4>
          <p>Pfizer's fordadistrogene movaparvovec program was halted in 2023 following a patient death in clinical trials. This underscores the critical importance of safety monitoring in gene therapy programs.</p>
        </div>
      </div>
    </div>

    <div id="crispr-trials" class="tab-content">
      <div class="info-box success">
        <h4>CRISPR/Cas9 — Editing Out the Mutation</h4>
        <p>CRISPR-based approaches aim to permanently correct or delete the disease-causing mutation from the genome, rather than introducing a new gene. This could provide a one-time permanent fix — but delivery to all muscles remains a major challenge.</p>
      </div>
      <div class="timeline">
        <div class="timeline-item">
          <div class="time-label">Broad Institute / Tessera</div>
          <h4>PBGENE-DMD</h4>
          <p>Uses prime editing technology (a next-generation CRISPR approach) to precisely correct DMD mutations without double-strand DNA breaks. IND application filed. Phase 1 trial expected to open 2025–2026.</p>
        </div>
        <div class="timeline-item">
          <div class="time-label">Dyne Therapeutics</div>
          <h4>FORCE Exon 51 &amp; Del-Zota</h4>
          <p>Dyne's FORCE platform delivers ASOs conjugated to a muscle-targeting antibody fragment (ITGA7), dramatically improving delivery to muscle tissue. Phase 2/3 trials underway for exon 51 skipping. Del-Zota targets exon 44.</p>
        </div>
        <div class="timeline-item">
          <div class="time-label">Wave Life Sciences</div>
          <h4>WVE-N531 (Exon 53)</h4>
          <p>A next-generation stereopure ASO for exon 53 skipping. Phase 2 FORWARD-53 trial shows higher dystrophin production than first-generation exon-53 drugs. Monthly dosing schedule.</p>
        </div>
      </div>
    </div>

    <div id="intl-access" class="tab-content">
      <div class="info-box">
        <h4>Global Trial Access &amp; Leading DMD Centers</h4>
        <p>DMD trials are conducted at specialized multidisciplinary centers across multiple countries. Most trials list sites at ClinicalTrials.gov. Key international centers include:</p>
      </div>
      <table class="styled-table">
        <thead><tr><th>Center</th><th>Country</th><th>Known Focus</th></tr></thead>
        <tbody>
          <tr><td>Nationwide Children's Hospital (NCH)</td><td>USA</td><td>Gene therapy trials, neuromuscular program, TREAT-NMD</td></tr>
          <tr><td>Great Ormond Street Hospital (GOSH)</td><td>UK</td><td>Pediatric DMD research, EU gene therapy trials</td></tr>
          <tr><td>Boston Children's Hospital</td><td>USA</td><td>Multidisciplinary DMD care, cardiac research</td></tr>
          <tr><td>Hospital for Sick Children (SickKids)</td><td>Canada</td><td>Corticosteroid trials, registry, respiratory care</td></tr>
          <tr><td>Radboud University Medical Centre</td><td>Netherlands</td><td>Exon-skipping pioneering research (van Ommen lab)</td></tr>
          <tr><td>Institut de Myologie (Paris)</td><td>France</td><td>Gene therapy (Genethon), AFM-Téléthon programs</td></tr>
        </tbody>
      </table>
      <div class="info-box success">
        <h4>How to Find Trials</h4>
        <p>Use ClinicalTrials.gov (search "Duchenne") or PPMD's clinical trial finder at parentprojectmd.org. The TREAT-NMD network maintains a global patient registry that connects patients to trials. NORD also maintains a registry for rare diseases including DMD.</p>
      </div>
      <div style="margin-top:20px;">
        <a href="https://clinicaltrials.gov/search?cond=duchenne+muscular+dystrophy" target="_blank" class="link-btn"><iconify-icon icon="mdi:flask"></iconify-icon> ClinicalTrials.gov</a>
        <a href="https://www.parentprojectmd.org/research/for-researchers-and-clinicians/clinical-trial-finder/" target="_blank" class="link-btn green"><iconify-icon icon="mdi:magnify"></iconify-icon> PPMD Trial Finder</a>
        <a href="https://www.treat-nmd.eu/dmd/registry/" target="_blank" class="link-btn orange"><iconify-icon icon="mdi:account-group"></iconify-icon> TREAT-NMD Registry</a>
      </div>
    </div>

    <div id="novel-trials" class="tab-content">
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon"><iconify-icon icon="mdi:atom"></iconify-icon></div>
          <h3>Stop Codon Readthrough</h3>
          <p>Ataluren (PTC124) is approved in some EU countries for DMD patients with nonsense mutations (~13% of all DMD). It allows ribosomes to read through premature stop codons. Multiple confirmatory trials are ongoing.</p>
        </div>
        <div class="card green">
          <div class="card-icon"><iconify-icon icon="mdi:bacteria"></iconify-icon></div>
          <h3>Utrophin Upregulation</h3>
          <p>Utrophin is a naturally occurring protein similar to dystrophin. Ezutromid and other utrophin modulators aim to upregulate utrophin to compensate for dystrophin deficiency. Phase 2 trials ongoing.</p>
        </div>
        <div class="card orange">
          <div class="card-icon"><iconify-icon icon="mdi:heart"></iconify-icon></div>
          <h3>Cardiac-Specific Trials</h3>
          <p>Several trials focus specifically on DMD cardiomyopathy, including gene therapy vectors targeting the heart and novel cardioprotective medications. The Cooperative International Neuromuscular Research Group (CINRG) runs longitudinal cardiac studies.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- RESEARCH -->
  <section id="research" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:microscope"></iconify-icon></div>
      <div><h2>Research Highlights</h2><p>Latest discoveries and scientific developments</p></div>
    </div>
    <div class="timeline">
      <div class="timeline-item">
        <div class="time-label">2024</div>
        <h4>Givinostat (Duvyzat) — FDA Approval</h4>
        <p>In March 2024, the FDA approved givinostat (Duvyzat, by Italfarmaco) for DMD — the first non-mutation-specific drug approved for DMD in the US. The Phase 3 trial showed significant slowing of muscle deterioration across all DMD mutation types.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">2024</div>
        <h4>Elevidys Expanded Approval</h4>
        <p>Sarepta Therapeutics received expanded FDA approval in June 2024, making Elevidys available to all ambulatory DMD patients ages 4 and older (previously limited to ages 4–5). This dramatically increased the eligible patient population.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">2023–2024</div>
        <h4>Cardiac Gene Therapy Research</h4>
        <p>Multiple research groups published data on AAV-mediated cardiac gene therapy in DMD mouse and dog models, showing restoration of cardiac function. Human cardiac-focused gene therapy trials are in planning stages.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">2023</div>
        <h4>Newborn Screening Programs</h4>
        <p>Several US states (including New York and Ohio) added DMD to newborn screening panels. Early detection (by CK levels) allows families to begin care planning, access trials, and start steroid therapy at the optimal developmental window.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">2022–2023</div>
        <h4>Exoskeleton and Assistive Robotics</h4>
        <p>Clinical studies of powered exoskeletons (EksoNR, ReWalk, Ekso Indego) in DMD demonstrate sustained ambulation beyond natural walking loss. Some centers now integrate exoskeleton therapy into standard DMD physiotherapy programs.</p>
      </div>
    </div>
  </section>

  <!-- PHYSIOTHERAPY -->
  <section id="physio" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:run"></iconify-icon></div>
      <div><h2>Physiotherapy &amp; Rehabilitation</h2><p>Movement, function, and quality of life</p></div>
    </div>
    <div class="info-box success">
      <h4>Why Physiotherapy Is Essential</h4>
      <p>Physiotherapy in DMD aims to maintain range of motion, delay contractures, support respiratory function, and maximize functional independence at every stage of the disease. It should be tailored to the patient's current motor level (ambulatory vs. non-ambulatory).</p>
    </div>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="mdi:walk"></iconify-icon></div>
        <h3>Ambulatory Phase</h3>
        <p>Gentle stretching, hydrotherapy, low-impact exercise (swimming, cycling), and ankle-foot orthoses (AFOs) to prevent equinus contracture. Avoid eccentric exercises (downhill walking, heavy lifting) that increase muscle damage.</p>
      </div>
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="mdi:wheelchair"></iconify-icon></div>
        <h3>Non-Ambulatory Phase</h3>
        <p>Posture management, spinal alignment, standing programs (standing frames/standers), upper limb function preservation, powered wheelchair optimization. Scoliosis monitoring (Cobb angle) every 6–12 months.</p>
      </div>
      <div class="card orange">
        <div class="card-icon"><iconify-icon icon="mdi:lungs"></iconify-icon></div>
        <h3>Respiratory Physiotherapy</h3>
        <p>Lung volume recruitment (LVR/breath stacking), manually assisted cough techniques, mechanical insufflation-exsufflation (CoughAssist), and monitoring of FVC (forced vital capacity) every 6 months from age 5.</p>
      </div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Night splints and orthotics <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>Night splints (ankle-foot orthoses worn during sleep) help maintain ankle dorsiflexion and delay development of calf contractures. Knee-ankle-foot orthoses (KAFOs) may extend the ambulatory period. Custom seating and spinal supports are essential once wheelchair use begins.</p>
      </div></div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Hydrotherapy and aquatic therapy <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>Warm-water pool therapy (32–34°C) is particularly beneficial in DMD. The buoyancy reduces load on weakened muscles, allowing movement that is impossible on land. Aquatic therapy can include walking, range-of-motion exercises, and recreational swimming. Safety protocols for pool entry/exit and emergency procedures are essential.</p>
      </div></div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Powered wheelchairs and assistive technology <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>Modern powered wheelchairs offer tilt-in-space, recline, and stand functions. Choosing the right chair early (often before full loss of ambulation) allows skill building and reduces fatigue. Integration with home automation (voice control, smart home) can dramatically increase independence. Eye-gaze and head-tracking systems support communication and device control.</p>
      </div></div>
    </div>
  </section>

  <!-- LIFESTYLE -->
  <section id="lifestyle" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:heart"></iconify-icon></div>
      <div><h2>Lifestyle</h2><p>Nutrition, mental health, education, and technology</p></div>
    </div>

    <div class="tabs">
      <button class="tab-btn active" onclick="switchTab(this,'nutrition')">Nutrition</button>
      <button class="tab-btn" onclick="switchTab(this,'mental')">Mental Health</button>
      <button class="tab-btn" onclick="switchTab(this,'education')">Education</button>
      <button class="tab-btn" onclick="switchTab(this,'tech')">Technology</button>
    </div>

    <div id="nutrition" class="tab-content active">
      <div class="info-box">
        <h4>Nutritional Considerations in DMD</h4>
        <p>Boys with DMD face dual nutritional challenges: steroid-induced weight gain in early years, and risk of malnutrition as swallowing difficulties (dysphagia) develop in later stages. Regular dietitian involvement is recommended.</p>
      </div>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon"><iconify-icon icon="mdi:food-apple"></iconify-icon></div>
          <h3>Anti-Inflammatory Diet</h3>
          <p>A Mediterranean-style diet rich in omega-3 fatty acids (fish, walnuts, flaxseed), vegetables, and whole grains may support muscle health and counteract steroid-related metabolic effects. Vitamin D and calcium supplementation is essential on steroids.</p>
        </div>
        <div class="card green">
          <div class="card-icon"><iconify-icon icon="mdi:scale-balance"></iconify-icon></div>
          <h3>Weight Management</h3>
          <p>Steroid therapy significantly increases appetite and weight gain. Maintaining healthy weight is important to preserve ambulatory function. Structured meal plans, low-glycemic foods, and avoiding excessive caloric intake help manage steroid-related obesity.</p>
        </div>
        <div class="card orange">
          <div class="card-icon"><iconify-icon icon="mdi:cup-water"></iconify-icon></div>
          <h3>Dysphagia &amp; Swallowing</h3>
          <p>Swallowing difficulties may develop as disease progresses. Speech-language pathologist (SLP) assessment for safe swallowing, modified food textures (IDDSI framework), and in severe cases gastrostomy (G-tube) or PEG tube placement for nutritional support.</p>
        </div>
      </div>
    </div>

    <div id="mental" class="tab-content">
      <div class="info-box">
        <h4>Mental Health in DMD</h4>
        <p>DMD affects not only physical function but also psychological well-being. Higher rates of anxiety, depression, ADHD, and autism spectrum features have been documented in DMD. Early neuropsychological assessment and support are part of comprehensive DMD care.</p>
      </div>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon"><iconify-icon icon="mdi:brain"></iconify-icon></div>
          <h3>Neurodevelopmental Profile</h3>
          <p>The dystrophin protein is expressed in the brain (Dp71 isoform). Cognitive differences, learning disabilities, and attention difficulties are more common in DMD. Neuropsychological evaluation helps identify strengths and develop educational accommodations.</p>
        </div>
        <div class="card green">
          <div class="card-icon"><iconify-icon icon="mdi:account-group"></iconify-icon></div>
          <h3>Peer Support &amp; Community</h3>
          <p>PPMD's online community, MDA's summer camps, and CureDuchenne's family events provide vital peer connections. Sibling support programs (for brothers/sisters of affected boys) are also available through national organizations.</p>
        </div>
        <div class="card orange">
          <div class="card-icon"><iconify-icon icon="mdi:head-heart"></iconify-icon></div>
          <h3>Transition to Adulthood</h3>
          <p>Transition planning should begin by age 14: planning for independent living, higher education or vocational training, adult medical care transfer, social security/disability benefits enrollment, and relationship and sexuality counseling.</p>
        </div>
      </div>
    </div>

    <div id="education" class="tab-content">
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon"><iconify-icon icon="mdi:school"></iconify-icon></div>
          <h3>Educational Rights</h3>
          <p>In the US, the Individuals with Disabilities Education Act (IDEA) guarantees an Individualized Education Program (IEP) for children with DMD. In the UK, the Education, Health and Care Plan (EHC) provides equivalent protections. Similar frameworks exist in Canada, Australia, and EU countries.</p>
        </div>
        <div class="card green">
          <div class="card-icon"><iconify-icon icon="mdi:laptop"></iconify-icon></div>
          <h3>Assistive Technology in Education</h3>
          <p>Voice-to-text software, adaptive keyboards, tablet-based writing aids, and remote learning tools support academic participation. Many schools now offer hybrid or distance learning options that benefit students with mobility limitations.</p>
        </div>
        <div class="card orange">
          <div class="card-icon"><iconify-icon icon="mdi:university"></iconify-icon></div>
          <h3>Higher Education</h3>
          <p>Many young adults with DMD attend university and pursue professional careers. Disability services offices provide accommodations (extended exam time, accessible housing, personal assistants). Organizations like PPMD offer scholarship programs for DMD patients and siblings.</p>
        </div>
      </div>
    </div>

    <div id="tech" class="tab-content">
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon"><iconify-icon icon="mdi:controller-classic"></iconify-icon></div>
          <h3>Gaming &amp; Digital Life</h3>
          <p>Many young men with DMD are enthusiastic gamers. Adaptive controllers (Xbox Adaptive Controller, Logitech Adaptive Gaming Kit), eye-tracking gaming interfaces, and head-mounted controls enable full gaming participation. Gaming communities provide important social connection.</p>
        </div>
        <div class="card green">
          <div class="card-icon"><iconify-icon icon="mdi:home-automation"></iconify-icon></div>
          <h3>Smart Home Integration</h3>
          <p>Voice-controlled smart home systems (Alexa, Google Home, Apple HomeKit), smart lighting, motorized beds, automated doors, and connected wheelchairs dramatically increase independence. Many local disability organizations offer smart home setup assistance.</p>
        </div>
        <div class="card orange">
          <div class="card-icon"><iconify-icon icon="mdi:phone-alert"></iconify-icon></div>
          <h3>Health Monitoring Apps</h3>
          <p>Wearable health monitors (heart rate, oxygen saturation), spirometry apps, and telemedicine platforms allow remote monitoring by DMD specialists. Apps like MOVR (from PPMD) enable patient-reported outcome tracking at home.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- PSYCHOLOGICAL SUPPORT -->
  <section id="psychological-approach" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:brain"></iconify-icon></div>
      <div><h2>Psychological Support</h2><p>For patients, families, and caregivers</p></div>
    </div>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="mdi:human-male-child"></iconify-icon></div>
        <h3>For the Child / Young Person</h3>
        <p>Child psychologists experienced in chronic illness can help with anxiety, depression, body image, school challenges, and identity development. Cognitive-behavioral therapy (CBT) is effective for managing DMD-related anxiety and depression.</p>
      </div>
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="mdi:human-male-female"></iconify-icon></div>
        <h3>For Parents &amp; Families</h3>
        <p>Parental grief, burnout, and anxiety are common. Organizations like PPMD, MDA, and CureDuchenne offer family support groups, online forums, and professional counseling referrals. Parent-to-parent matching programs connect newly diagnosed families with experienced ones.</p>
      </div>
      <div class="card orange">
        <div class="card-icon"><iconify-icon icon="mdi:account-heart"></iconify-icon></div>
        <h3>For Caregivers</h3>
        <p>Caregiver fatigue and secondary trauma are real. Respite care programs, caregiver support groups, and self-care planning are essential. Many national muscular dystrophy organizations offer caregiver support services and information on respite care funding.</p>
      </div>
    </div>
    <div class="info-box">
      <h4>Multidisciplinary Psychological Care</h4>
      <p>Leading DMD centers integrate psychological and social work support directly into the multidisciplinary team. Palliative care consultation (focused on quality of life, not end of life) should begin early and continue throughout the disease course. Advance care planning discussions, though difficult, empower families and ensure that medical decisions align with personal values.</p>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Sibling support <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>Siblings of boys with DMD may experience feelings of guilt, neglect, resentment, or sadness. Dedicated sibling support programs are available through MDA, PPMD, and many hospital-based DMD programs. School counselors should also be informed to provide additional support.</p>
      </div></div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">Palliative care and advance planning <span class="arrow">&#9660;</span></div>
      <div class="accordion-body"><div class="inner">
        <p>Pediatric palliative care does not mean giving up hope — it means maximizing quality of life at every stage. Palliative care teams help families discuss ventilation decisions, hospitalization preferences, and personal goals. These conversations are best had proactively, not during a crisis. Many families report that early palliative care engagement leads to better outcomes and less regret.</p>
      </div></div>
    </div>
  </section>

  <!-- STORIES -->
  <section id="stories" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:account-voice"></iconify-icon></div>
      <div><h2>Stories of Courage</h2><p>Voices from the DMD community</p></div>
    </div>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="mdi:movie"></iconify-icon></div>
        <h3>Darius Weems</h3>
        <p>Darius had DMD and became famous through the documentary "Darius Goes West" (2007), in which his friends took him on a road trip across the US. The film raised over $3 million for DMD research and became a symbol of joy and friendship in the face of progressive illness. Darius passed away in 2016 at age 27.</p>
      </div>
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="mdi:gamepad-variant"></iconify-icon></div>
        <h3>Mats Steen — "Ibelin"</h3>
        <p>Mats was a Norwegian young man with DMD who lived much of his life through the online game World of Warcraft, where he created a beloved character, Ibelin. After his death at 25, his parents discovered the deep friendships and community he had built online. The Netflix documentary "The Remarkable Life of Ibelin" (2024) went on to win an Oscar, shining a light on the power of digital connection for those with disabilities.</p>
      </div>
      <div class="card orange">
        <div class="card-icon"><iconify-icon icon="mdi:run-fast"></iconify-icon></div>
        <h3>Jake Marrazzo</h3>
        <p>Jake was diagnosed with DMD at age 4, but went on to become a high school football team manager, motivational speaker, and advocate for DMD research. His story, featured in Sports Illustrated, inspired a broader conversation about inclusion, potential, and redefining what it means to participate in sports.</p>
      </div>
    </div>
    <div class="info-box success">
      <h4>The DMD Community is Worldwide</h4>
      <p>DMD families, advocates, and researchers form a passionate global community. PPMD's annual conference, CureDuchenne's HOPE events, and MDA's conferences bring hundreds of families together each year. Online communities (Facebook groups, Discord servers, Reddit) provide 24/7 peer support across time zones.</p>
    </div>
  </section>

  <!-- BOOKS & MEDIA -->
  <section id="books" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:book-open"></iconify-icon></div>
      <div><h2>Books &amp; Media</h2><p>Films, books, and podcasts about DMD</p></div>
    </div>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="mdi:book"></iconify-icon></div>
        <h3>Children's Books</h3>
        <p><em>"My Brother Dylan"</em> — A story for young children about a brother with DMD. <em>"Wheels &amp; Wings"</em> — An illustrated book exploring life with a wheelchair. These books help siblings and classmates understand DMD in age-appropriate ways.</p>
      </div>
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="mdi:movie-open"></iconify-icon></div>
        <h3>Films &amp; Documentaries</h3>
        <p><em>"Darius Goes West"</em> (2007) — Road trip documentary and DMD fundraising landmark. <em>"The Remarkable Life of Ibelin"</em> (2024, Netflix) — Oscar-winning documentary about Mats Steen and his online world. Both are widely used in DMD awareness campaigns.</p>
      </div>
      <div class="card orange">
        <div class="card-icon"><iconify-icon icon="mdi:microphone"></iconify-icon></div>
        <h3>Podcasts</h3>
        <p><em>"Decode Duchenne"</em> by PPMD — covers clinical updates, research news, and family stories. <em>"Muscular Dystrophy Podcast"</em> by MDA — broader NMD coverage including DMD. <em>"The DMD Podcast"</em> — parent and patient perspectives on living with Duchenne.</p>
      </div>
    </div>
  </section>

  <!-- ACTION PLAN -->
  <section id="action" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:clipboard-check"></iconify-icon></div>
      <div><h2>7-Step Action Plan</h2><p>A roadmap from diagnosis</p></div>
    </div>
    <div class="timeline">
      <div class="timeline-item">
        <div class="time-label">Step 1</div>
        <h4>Confirm the Genetic Diagnosis</h4>
        <p>Ensure full genetic sequencing (NGS panel or MLPA) to identify the exact mutation, exon(s) affected, and reading frame impact. This determines treatment eligibility (exon skipping, gene therapy, ataluren). Get a second opinion at a specialized DMD center if needed.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Step 2</div>
        <h4>Build a Multidisciplinary Care Team</h4>
        <p>A comprehensive DMD team includes: pediatric neurologist/neuromuscular specialist, cardiologist, pulmonologist, physiotherapist, occupational therapist, speech-language pathologist, dietitian, psychologist, and social worker. Seek care at an MDA Care Center or equivalent specialized DMD center.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Step 3</div>
        <h4>Start Corticosteroid Therapy at the Right Time</h4>
        <p>Corticosteroids are typically started when motor function plateaus (usually ages 4–6). Discuss with your neurologist which steroid (prednisone, deflazacort, or vamorolone) and which dosing schedule is most appropriate. Monitor for side effects from the start.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Step 4</div>
        <h4>Start Cardiac and Respiratory Monitoring</h4>
        <p>Echocardiogram and ECG every 1–2 years (annual after age 10). Pulmonary function tests (FVC, PEF, SNIP) every 6 months from age 5. Early initiation of ACE inhibitors and beta-blockers if cardiomyopathy is detected. Plan for non-invasive ventilation when FVC drops below 50%.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Step 5</div>
        <h4>Check Eligibility for Mutation-Specific Therapies</h4>
        <p>Based on the confirmed genetic mutation, assess eligibility for exon-skipping drugs (Exondys 51, Vyondys 53, Viltepso, Amondys 45), gene therapy (Elevidys), givinostat (Duvyzat), or ataluren (if nonsense mutation). Update assessment whenever new therapies are approved.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Step 6</div>
        <h4>Connect with the Community &amp; Find Trials</h4>
        <p>Register with PPMD, MDA, TREAT-NMD, and the Duchenne Registry. Join a support group. Search ClinicalTrials.gov for active trials matching your mutation. Consider enrolling in natural history studies which provide care and contribute to future treatment approvals.</p>
      </div>
      <div class="timeline-item">
        <div class="time-label">Step 7</div>
        <h4>Plan for the Future — Early and Continuously</h4>
        <p>Address school accommodations, physical adaptations at home, transition planning from pediatric to adult care, financial planning (special needs trusts, ABLE accounts in the US), and advance care planning. PPMD's "Certified Duchenne Care Center" program helps ensure standardized, comprehensive care.</p>
      </div>
    </div>
  </section>

  <!-- RESOURCES -->
  <section id="resources" class="section fade-in">
    <div class="section-header">
      <div class="sec-icon"><iconify-icon icon="mdi:link"></iconify-icon></div>
      <div><h2>Resources</h2><p>Organizations, registries, and databases</p></div>
    </div>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon"><iconify-icon icon="mdi:account-group"></iconify-icon></div>
        <h3>International Organizations</h3>
        <p>
          <strong>PPMD</strong> (Parent Project Muscular Dystrophy) — parentprojectmd.org<br>
          <strong>CureDuchenne</strong> — cureduchenne.org<br>
          <strong>MDA</strong> (Muscular Dystrophy Association) — mda.org<br>
          <strong>World Duchenne Organization</strong> — worldduchenne.org<br>
          <strong>TREAT-NMD</strong> — treat-nmd.eu<br>
          <strong>AFM-Téléthon</strong> (France) — afm-telethon.fr
        </p>
      </div>
      <div class="card green">
        <div class="card-icon"><iconify-icon icon="mdi:hospital-building"></iconify-icon></div>
        <h3>Leading DMD Centers</h3>
        <p>
          <strong>Nationwide Children's Hospital</strong> — Columbus, Ohio<br>
          <strong>Great Ormond Street Hospital</strong> — London, UK<br>
          <strong>Boston Children's Hospital</strong> — Boston, USA<br>
          <strong>Hospital for Sick Children (SickKids)</strong> — Toronto, Canada<br>
          <strong>Institut de Myologie</strong> — Paris, France<br>
          <strong>MDA Certified Care Centers</strong> — mda.org/care/care-centers
        </p>
      </div>
      <div class="card orange">
        <div class="card-icon"><iconify-icon icon="mdi:database"></iconify-icon></div>
        <h3>Research &amp; Trial Databases</h3>
        <p>
          <strong>ClinicalTrials.gov</strong> — Search: "Duchenne Muscular Dystrophy"<br>
          <strong>Duchenne Registry</strong> — duchenneregistry.org (patient self-reported)<br>
          <strong>TREAT-NMD Registry</strong> — treat-nmd.eu/dmd/registry<br>
          <strong>PubMed</strong> — ncbi.nlm.nih.gov/pubmed<br>
          <strong>Neuromuscular Disease Center</strong> — neuromuscular.wustl.edu<br>
          <strong>NORD</strong> — rarediseases.org
        </p>
      </div>
    </div>
  </section>

  <!-- CTA -->
  <div class="carepedia-cta">
    <h3>Was this information helpful?</h3>
    <p>CarePedia is a free resource for rare disease families. We update our portals regularly with the latest research and treatments.</p>
    <a href="https://carepedia.org" class="cta-btn"><iconify-icon icon="mdi:home"></iconify-icon> Back to CarePedia Home</a>
  </div>

  <footer class="footer">
    <div class="credit-bar">
      <span>CarePedia DMD Hub &copy; 2025</span>
      <span>|</span>
      <span>Information updated regularly. Always consult your medical team.</span>
      <a href="https://carepedia.org/request" class="portal-request-btn"><iconify-icon icon="mdi:plus-circle"></iconify-icon> Request a Disease Portal</a>
    </div>
  </footer>

</main>

<button class="scroll-top" id="scrollTop" onclick="window.scrollTo({top:0,behavior:'smooth'})">
  <iconify-icon icon="mdi:chevron-up"></iconify-icon>
</button>

<script>
function toggleMenu() {
  const sidebar = document.getElementById('sidebar');
  const toggle = document.getElementById('menuToggle');
  const overlay = document.getElementById('overlay');
  sidebar.classList.toggle('open');
  toggle.classList.toggle('open');
  overlay.classList.toggle('active');
}
function closeMenu() {
  document.getElementById('sidebar').classList.remove('open');
  document.getElementById('menuToggle').classList.remove('open');
  document.getElementById('overlay').classList.remove('active');
}
function navigateTo(id) {
  closeMenu();
  const el = document.getElementById(id);
  if (el) el.scrollIntoView({ behavior: 'smooth' });
  document.querySelectorAll('.sidebar nav a').forEach(a => a.classList.remove('active'));
  const link = document.querySelector('.sidebar nav a[href="#' + id + '"]');
  if (link) link.classList.add('active');
}
function toggleAccordion(header) {
  const body = header.nextElementSibling;
  const isOpen = header.classList.contains('open');
  document.querySelectorAll('.accordion-header.open').forEach(h => {
    h.classList.remove('open');
    h.nextElementSibling.style.maxHeight = '0';
  });
  if (!isOpen) {
    header.classList.add('open');
    body.style.maxHeight = body.scrollHeight + 'px';
  }
}
function switchTab(btn, tabId) {
  const section = btn.closest('section') || btn.closest('.section') || btn.parentElement.parentElement;
  section.querySelectorAll('.tab-btn').forEach(b => b.classList.remove('active'));
  section.querySelectorAll('.tab-content').forEach(c => c.classList.remove('active'));
  btn.classList.add('active');
  const target = document.getElementById(tabId);
  if (target) target.classList.add('active');
}

// Scroll progress bar
window.addEventListener('scroll', () => {
  const scrolled = window.scrollY;
  const total = document.body.scrollHeight - window.innerHeight;
  document.getElementById('scrollBar').style.width = (scrolled / total * 100) + '%';
  document.getElementById('scrollTop').classList.toggle('visible', scrolled > 400);
  // Update active nav link
  const sections = document.querySelectorAll('section[id], div.section[id]');
  let current = '';
  sections.forEach(sec => {
    if (window.scrollY >= sec.offsetTop - 200) current = sec.id;
  });
  document.querySelectorAll('.sidebar nav a').forEach(a => {
    a.classList.toggle('active', a.getAttribute('href') === '#' + current);
  });
});

// Fade-in observer
const observer = new IntersectionObserver(entries => {
  entries.forEach(e => { if (e.isIntersecting) e.target.classList.add('visible'); });
}, { threshold: 0.1 });
document.querySelectorAll('.fade-in').forEach(el => observer.observe(el));
</script>
</body>
</html>
